Lanreotide Acetate Injection
NDC Package 76282-720-67

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Lanreotide Acetate injection is a medication a long-acting form of lanreotide. This formulation utilizes a injection delivery system. Marketed by Exelan Pharmaceuticals, Inc., this product is identified by NDC 76282-720 and is authorized under FDA application ANDA217193.

Identification & Billing

NDC Package Code
76282-720-67
Package Description
1 POUCH in 1 CARTON / 1 SYRINGE in 1 POUCH / .5 mL in 1 SYRINGE
Product Code
76282-720
11-Digit Billing Format
76282072067
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 749811 - lanreotide 60 MG in 0.2 ML Prefilled Syringe
  • RxCUI: 749811 - 0.2 ML lanreotide 300 MG/ML Prefilled Syringe
  • RxCUI: 749811 - lanreotide 60 MG per 0.2 ML (as lanreotide acetate) Prefilled Syringe
  • RxCUI: 749814 - lanreotide 120 MG in 0.5 ML Prefilled Syringe
  • RxCUI: 749814 - 0.5 ML lanreotide 240 MG/ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Lanreotide Acetate
Non-Proprietary Name
Lanreotide Acetate
Substance Name
Lanreotide Acetate
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
LANREOTIDE ACETATE 120 mg/.5mL
Pharmacologic Class
Usage Information
This medication is a long-acting form of lanreotide. Lanreotide is used to treat a condition called acromegaly that occurs when the body makes too much of a certain natural substance called growth hormone. It is used when surgery or radiation treatment have not been fully successful or cannot be used. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Lanreotide works by decreasing the amount of growth hormone to normal levels. This drug is not a cure for acromegaly. It is used for the long-term treatment of this condition. This medication is also used to treat certain cancer or tumors of the stomach, intestines, or pancreas. It may help to slow down the growth of these tumors. Lanreotide is also used to treat carcinoid syndrome. It may help reduce the need to use another medication to treat diarrhea or flushing caused by carcinoid syndrome.

Regulatory & Marketing

Labeler Name
Exelan Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA217193
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-30-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J1930
Source: PDAC
INJECTION, LANREOTIDE, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76282-720-67 identifies a specific commercial package of 1 pouch in 1 carton / 1 syringe in 1 pouch / .5 ml in 1 syringe of Lanreotide Acetate, a human prescription drug labeled by Exelan Pharmaceuticals, Inc.. This injection is formulated for subcutaneous use and contains lanreotide acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Exelan Pharmaceuticals, Inc. on May 30, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is a long-acting form of lanreotide. Lanreotide is used to treat a condition called acromegaly that occurs when the body makes too much of a certain natural substance called growth hormone. It is used when surgery or radiation treatment have not been fully successful or cannot be used. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Lanreotide works by decreasing the amount of growth hormone to normal levels. This drug is not a cure for acromegaly. It is used for the long-term treatment of this condition. This medication is also used to treat certain cancer or tumors of the stomach, intestines, or pancreas. It may help to slow down the growth of these tumors. Lanreotide is also used to treat carcinoid syndrome. It may help reduce the need to use another medication to treat diarrhea or flushing caused by carcinoid syndrome.

How is this Exelan Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76282072067. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76282-720-67
11-Digit CMS (5-4-2)
76282-0720-67

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.